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BACKGROUND: Patients with transient loss of con-
sciousness (TLOC) have poor health-related quality of
life (HR-QoL).
OBJECTIVE: To test the reliability, validity, and respon-
siveness of the disease-specific Syncope Functional
Status HR-QoL Questionnaire (SFSQ), which yields
two summary scales—impairment score (IS) and fear–
worry score (FWS).
DESIGN: Cohort-study.
PARTICIPANTS: 503 adult patients presenting with
TLOC.
MEASUREMENTS: HR-QoL was assessed using the
SFSQ and the Short Form-36 (SF-36) after presentation
and 1 year later. To test reliability, score distributions,
internal consistency, and test–retest reliability were
assessed. To assess validity, scores on the SFSQ and
the SF-36 were compared. Clinical validity was tested
using known-group comparison. Responsiveness was
assessed by comparing changes in SFSQ scores with
changes in health status and clinical condition.
RESULTS: Response rate was 82% at baseline and 72%
at 1-year follow-up. For all scales the full range of
scores was seen. Score distributions were asymmetri-
cal. Internal consistency was high (alpha=0.88 for IS,
0.92 for FWS). Test–retest reliability was moderate to
good for individual items and high for summary scales
(inter-class correlation=0.78 for both IS and FWS).
Correlations between SFSQ scores and the SF-36 were
modest. The SFSQ did not discriminate between
patients differing in age and gender but did discrimi-
nate between patients differing in number of episodes
and comorbid conditions. Changes in SFSQ scores were
related to changes in health status and the presence of
recurrences but did not vary by TLOC diagnosis.
CONCLUSION: The SFSQ is an adequately reliable,
valid, and responsive measure to assess HR-QoL in
patients with TLOC.
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INTRODUCTION
Episodes of transient loss of consciousness (TLOC) are very
common
1,2 and can be caused by a large number of clinical
disorders.
3 Most episodes of TLOC are caused by benign
conditions like vasovagal syncope.
2 Only a small group of
patients with TLOC suffer from potentially lethal cardiac
arrhythmias.
4
Patients with TLOC have a health-related quality of life (HR-
QoL) comparable to that of patients with serious chronic
conditions like rheumatoid arthritis as assessed with generic
HR-QoL questionnaires.
5–7 The absence of physical symptoms
between episodes in combination with the risk of recurrences
or even death
4,8 makes it a unique clinical syndrome. A
disease-specific HR-QoL questionnaire should provide greater
insight in the impairment of patients with TLOC than a generic
HR-QoL questionnaire.
In an earlier study, Linzer et al. described the development
and preliminary validation of the disease specific Syncope
Functional Status Questionnaire (SFSQ).
9 Limited validation
of the instrument was performed in 49 severely affected
American patients
9 against the Sickness Impact Profile
10 and
Symptom Checklist 90-R.
11 More extensive validation in a
larger and more representative group of patients has not yet
been performed.
The full evaluation of any health measurement scale
requires establishing its reliability, validity, and responsive-
ness to change.
12 The objective of the present study was
therefore to test the reliability, validity and responsiveness of
the SFSQ in a large cohort of patients presenting with TLOC.
METHODS
Subjects
This study is part of the Fainting Assessment Study (FAST);
FAST was designed to asses the diagnostic yield and accuracy
of attending physicians in patients presenting with TLOC (Van
Dijk et al., submitted for publication).
6,7 The Academic Medical
Center (AMC) is a first-line referral center for patients from the
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1280surrounding area and a speciality center for patients with
TLOC from the Dutch population. Adult patients presenting to
the AMC, between January 2000 and July 2002, with at least
one episode of TLOC in the 12 months before presentation
were eligible for the study. TLOC was defined as self-limiting
episodes of loss of consciousness, not lasting longer than
1 hour. Patients incapable of reading Dutch and patients with
a physical/mental impairment that prevented their completing
the questionnaires were excluded. All patients gave informed
consent. This study was approved by the Medical Ethical
Committee of our institution.
Data Collection
Clinical Data. At presentation, an initial clinical evaluation was
performed, including in most cases a standardized history, a
physical examination and a 12-lead ECG.
3 If no diagnosis
could be made after initial evaluation, additional cardiologic
testing and autonomic function testing were performed.
Data on comorbidity was obtained from the medical records
and numerically converted using the Charlson comorbidity
index.
13 Clinical follow-up data were obtained by sending a
clinical follow-up questionnaire to all patients at 1 and at least
2 years after presentation. If a questionnaire was not returned,
the patient, a family member, the general physician, or the
medical insurance company was contacted by telephone to
obtaintherequestedinformation.Finaldiagnosesweremadeby
an expert committee after 2 years of follow-up (Van Dijk et al.,
submitted for publication).
Quality-of-life Data. HR-QoL was assessed using the SFSQ as
the questionnaire under study
9 and the Short Form-36 (SF-36)
as a comparative measure.
14
The SFSQ consists of 11 yes/no questions, assessing the
areas in which syncope interferes with a patient’s daily life,
and three eight-point Likert-scale questions that assess a
patient’s fear and worry about syncope. The impairment score
was calculated by dividing the number of areas in which
syncope interferes with the patient’s life (ranging from 0–11) by
the total number of areas applicable to a patient’s life,
multiplied by 100. This score ranges from 0 to 100, with
higher scores representing more interference in the patient’s
life. The three Likert-scale questions were linearly converted to
a0 –100 scale and averaged to calculate the fear–worry score,
also scaled from 0 to 100 with higher scores indicating more
fear and worry. A syncope dysfunction score (SDS) was then
calculated as the statistical mean of the impairment score and
the fear–worry score.
9 The questionnaire was translated into
Dutch by means of the forward–backward method.
The SF-36 is a self-administered scale that measures HR-
QoL by scoring responses to standardized questions. The SF-
36 provides eight scale scores, a score for reported health
transition, and two summary scale scores.
14 Translation,
validation, and norming of the Dutch language version have
been performed earlier by Aaronson et al.
15
All patients received the questionnaires with a return
envelope directly after their initial presentation to our hospital.
Follow-up questionnaires were sent to the patients home
addresses 1 year after initial presentation. Nonrespondents
received a written reminder, which was sent 2 and 4 weeks
after sending the questionnaires.
To assess test–retest reliability, a convenience sample of 52
respondents to the first questionnaire was asked to fill out the
SFSQ again 1 week after they returned the first questionnaire.
A 1-week period was chosen to minimize both memory bias
and relevant changes in clinical condition.
16
Analysis
All HR-QoL questionnaires were entered into an SPSS data-
base by two different people. Differences were checked and
corrected according to data on the original questionnaire. All
analyses were performed using SPSS version 11.5.
Sociodemographic and clinical data were expressed as
percentages for categorical data and mean (SD) or median
(quartiles) for numerical data. Sociodemographic and clinical
data of respondents and nonrespondents were compared
using a chi-square test, t test, and a Mann–Whitney U test
where appropriate.
Reliability. Score distributions (skew, floor and ceiling effects,
and missing items) were examined for the SFSQ (impairment
score, fear–worry score and overall SDS). To assess internal
consistency of the impairment score the Kuder–Richardson
formula 20 (KR-20) was used,
17 while the fear–worry score was
evaluated using Cronbach’s alpha. An alpha of >0.7 was
considered internally consistent.
12,18
Test–retest reliability of the SFSQ was assessed by testing
the mean difference in scores, displayed as mean difference
with 95% CI and intraclass correlation (ICC; two-way mixed
model; consistency definition). To compare the results of the 11
yes/no questions, we used the kappa statistic (0.2–0.4 fair
agreement; 0.4–0.6 moderate; 0.6–0.8 good; >0.8 excellent
agreement). Correlation between the Likert questions at both
moments was assessed using Pearson’s correlation coefficient
(r>0.4=moderate correlation; r>0.75=high correlation).
12
Validity. To assess the validity of the SFSQ scale scores, we
compared them to the inverse results of the subscales of the SF-
36. It was expected that the impairment score would show high
correlation with physical functioning (PF), role functioning
physical (RP) and social functioning (SF). The fear–worry score
was expected to show high correlation with mental health (MH),
and the SDS with the general health (GH) domain. The relations
between the scale scores were calculated using Pearson’s
correlation coefficient (r). An r<0.4 was considered to indicate
low, r>0.4 moderate, and r>0.75 high correlation.
12
Clinical Validity. The method of known-group comparison
19
was used to determine the extent to which the SFSQ and the
SF-36 were able to discriminate between mutually exclusive
subgroups of patients, differing in age, gender, and number of
TLOC episodes. We expected the SF-36 to discriminate
between patients with differences in comorbid conditions
other than TLOC, but not the SFSQ, because the SFSQ aims
to specifically assess impairment caused by syncopal episodes.
Results were displayed as mean differences (95% CI) and
compared using a Student’s t test.
Responsiveness. Changes in SFSQ scores were expected to be
in agreement with the perceived change in health status in
1281 van Dijk et al.: Validation of a Syncope HR-QoL Questionnaire JGIMpatients after 1 year follow-up. Based on the five answering
options to the transition question in the SF-36 (compared to
1 year ago, how would you rate your health in general now),
patients were divided into five groups. The changes in SFSQ
scores were calculated per group and displayed as mean
(standard error of the mean). Differences were tested using
ANOVA.
Responsiveness of the SFSQ was also tested by comparing
changes between baseline and 1-year follow-up scale scores
with changes in clinical condition during follow-up. These
changes were defined as: (1) presence or absence of recur-
rences during follow-up,
20,21 (2) a diagnosis for the episodes or
not,
7 and (3) diagnostic category.
7 Differences were assessed
using Student’s t test or ANOVA.
RESULTS
Subjects
From January 2000 till July 2002, 503 patients were enrolled
in FAST. Thirty-five patients were excluded from this HR-QoL
study because of language problems (n=14) or being physically
or mentally unable to complete the questionnaires (n=21). Of
the remaining 468 patients, 385 (82%) returned their ques-
tionnaires. At 1-year follow-up, 268 (72%) of the original
respondents filled in the questionnaires again. Twelve patients
were excluded because of death during the follow-up period
(n=10), severe dementia (n=1), and detention (n=1). Fifty-two
patients completed the SFSQ two times for the test–retest
analysis with a mean interim period of 8 days (SD 6.9). The
sociodemographic and clinical characteristics of the respon-
dents and nonrespondents at baseline and 1-year follow-up
are displayed in Table 1. Nonrespondents were significantly
younger, more often female, and had experienced fewer
episodes of TLOC than respondents.
Reliability
Table 2 lists the means, SDs, medians, and ranges for the
summary scores of the SFSQ. For all scales, the full range of
possible scores was seen. Score distributions were asymmet-
rical, with large peaks at 0 (no impairment) for all scales. The
number of missing values ranged from 2.1% (relationship with
family/ friends) to 5.2% (use of public transportation). Internal
consistency of the impairment score was 0.88, and it was 0.92
of the fear–worry score.
Test–retest. Mean kappa for the 11 yes/no questions was good
(0.61), and kappas range from moderate to good (0.41–0.75).
Correlation for the Likert-scale questions was moderate (0.56–
0.60), whereas the ICC for the summary scales was high (0.78
for all scales). There is no statistically significant difference
between the baseline and retest questionnaire scale scores.
Validity
Correlations between the scale scores of the SFSQ and the SF-
36 are low to moderate, ranging from 0.30 to 0.62 (Table 3).
The impairment score shows moderate correlation with the PF,
RP, and SF scores (0.52, 0.54, and 0.58). The correlation
between the fear–worry score and MH is moderate (0.48) but
higher than the correlation with any other scale. The SDS
shows moderate correlation with GH (0.50) and shows similar
correlations with other scales scores of the SF-36.
Table 1. Sociodemographic and Clinical Characteristics of Study Subjects Completing Baseline and Follow Up Surveys
6,7
Baseline survey Follow up survey
Respondents
(n=385)
Non-respondents
(n=83)
Respondents
(n=268)
Non-respondents
(n=105)
Age (mean; SD)*
† 52 (19) 46 (19) 53 (18) 46 (19)
Male (%)
† 58% 49% 63% 41%
Highest educational level (%)
Elementary school 7.6% 20% 8.4% 9.3%
High school 18% 17% 18% 20%
Lower vocational education 16% 8.6% 16% 12%
Intermediate vocational education 27% 23% 25% 33%
College 23% 20% 24% 20%
University 9.0% 11% 8.4% 12%
Months of syncopal problems (median; quartiles)* 18 (2–96) 6.0 (0.3–36) 24 (2–120) 12 (4–72)
Lifetime syncopal episodes (median; quartiles)* 3 (2–10) 2 (1–5) 3 (1–10) 4 (2–13)
Syncopal episodes last 12 months (median; quartiles)
† 2( 1 –3) 1 (1–3) 1 (1–3) 2 (1–4)
Presyncopal episodes/month (median; quartiles) 0 (0–2) 0 (0–4) 0 (0–2) 0 (0–2)
Injury caused by syncope (%) 34.4% 30% 31.9% 38%
Charlson comorbidity index (median; quartiles) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–0.5)
Diagnosis after 2-year follow-up (%)
†
No diagnosis 9.9% 18% 7.5% 13%
Reflex syncope 75% 72% 77% 74%
Cardiac syncope 6.5% 4.8% 8.2% 1.0%
Neurological 2.6% 3.6% 3.0% 1.9%
Psychogenic pseudosyncope 6.0% 1.2% 4.9% 9.5%
Metabolic 0.3% 0.0% 0.0% 1.0%
*Difference between baseline respondents and nonrespondents significant at p=0.05
†Difference between follow up respondents and nonrespondents significant at p=0.05
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The SDS did not discriminate between patients differing in age
and gender. Patients with more than one episode in the year
before presentation showed a significantly poorer HR-QoL on
all SFSQ scales than patients with one episode before presen-
tation. The impairment score was significantly poorer in
patients with comorbid conditions than in patients without
comorbid conditions (Table 4). These differences were compa-
rable to the minimally important difference for these scales
7
and, therefore, can also be considered clinically relevant. The
scores on the physical component summary of the SF-36 were
different for subgroups of patients differing in gender, number
of episodes, and Charlson score. The mental component
summary (MCS) scores were not different between any of the
subgroups.
Responsiveness
The changes in the scale scores of the SFSQ between baseline
and 1-year follow-up, per category of perceived change in
health status, are displayed in Figure 1. Changes are linearly
related to the change in health status and significantly
different from each other (ANOVA; p=<0.01). The improvement
in impairment score (mean difference 11.8; p<0.01) and in
SDS (mean difference 8.2; p=0.02) was larger in patients
without recurrences during follow-up than in patients with
recurrences. The changes were not different between patients
with or without a diagnosis or with different diagnoses.
DISCUSSION
Summary of Results
In this study we examined the reliability, validity, and respon-
siveness of a disease-specific functional status questionnaire
for patients with syncope. The internal consistency of the
impairment score and fear–worry score items was high with
alphas of 0.88 and 0.92, respectively. Test–retest reliability was
moderate to good for the 11 yes/no impairment questions,
moderate for the Likert-scale fear–worry questions, and high
for the summary scale (SDS). Validity was moderate when
comparing the summary scales of the SDS with comparable
scale scores of the SF-36. The SFSQ showed adequate
discriminative properties between some of the clinically de-
fined subgroups of patients but not on sociodemographically
defined patient subgroups. This finding was in concordance
with the results of the SF-36. Responsiveness to perceived
change in health status and the presence of recurrence during
follow-up was good.
Reliability
Both scale scores and the SDS show a large floor effect. This
indicates that the SFSQ is not very sensitive to detecting
differences between patients with a low impact of the episodes
on their lives, i.e., good HR-QoL scores. Thus, when studying a
relatively healthy population, the SFSQ might not be ade-
quately sensitive. This could in part be the consequence of the
dichotomous choices (yes/no) for the impairment questions.
To make the instrument more sensitive to small changes in
relatively healthy subjects, one could replace the yes/no
response scale with a five-point Likert scale. This would likely
lead to the instrument being more sensitive to changes in
clinical conditions in all patients. Furthermore, in the existing
scoring system, all areas of impairment are considered equally
important; these questions may benefit from a weighting
system. In future use, we also recommend not combining the
impairment score and fear–worry score to obtain the SDS, as
the separate scale scores may provide more valid information.
The number of missing items is low, indicating a high
acceptability of the questionnaire. Although we expected the
question on sexual functioning would be considered inappro-
priate by some, this question did show equal acceptability.
The impairment score is initially based on 11 questions. In
cases where patients have “not applicable” responses (e.g.,
when the patient does not drive, does not work, has no
partner, is isolated socially, and is not sexually active), the
utility of the instrument may be diminished. For future
iterations of the questionnaire, the term “partner” could be
added to the question “does syncope interfere with your
relation with spouse/boyfriend/girlfriend” to make the ques-
tion applicable to more patients.
The internal consistency of the measure is comparable to
that found in the earlier study by Linzer et al.
9 The test–retest
method shows that the within-subject variability is quite small
when comparing the results to the mean changes seen in
patients with different changes in health status (Fig. 1). This
should enable researchers to use the SFSQ in clinical trials
with relatively small sample sizes,
22 keeping in mind that the
Table 3. Correlation (r) Between Scale Scores of the SFSQ and Scale Scores of the SF-36 at Baseline
SFSQ
SF-36
PF RP BP GH VT SF RE MH
Impairment score 0.52 0.54 0.38 0.44 0.46 0.58 0.50 0.35
Fear–worry score 0.33 0.39 0.32 0.39 0.42 0.45 0.44 0.48
SDS 0.51 0.56 0.45 0.50 0.53 0.62 0.56 0.50
All correlations are significant at the 0.01 level. Bold: correlations hypothesized to be high
PF=physical functioning, RP= rolephysical, BP= bodily pain, GH=general health, VT= vitality, SF=social functioning, RE= roleemotional, MH= mental health
Table 2. Score Distributions of the Summary Scales (Impairment
Score and Fear–Worry Score) and Overall Score (SDS) of the SFSQ
Mean SD Median Range
Impairment score 32.8 33.5 25.0 0–100
Fear–worry score 40.3 28.1 38.1 0–100
SDS 36.9 26.4 34.4 0–100
SDS range from 0 to 100; higher score = more impairment
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population in which it was tested. Our population was quite
large and heterogeneous; therefore, these results might differ
in a more homogeneous population.
23 Furthermore,the respon-
dents in our population differed from the nonrespondents,
which also might affect the generalizability of our results.
Validity
The correlation was moderate between the scores of the SFSQ
and the preselected scales of the SF-36. Although these
correlations are among the highest correlations, they are not
markedly different from the correlations with the other scale
scores of the SF-36. The relatively high correlation of the
impairment score with the RE scale can be explained by the
fact that the questions that comprise the RE scale are work-
related. The fear–worry score shows moderate correlation with
the MH scale of the SF-36. A possible explanation for this
moderate correlation can be that the items of the SF-36 focus
on MH in general, whereas the SFSQ focuses on fear and worry
on account of episodes of TLOC. Individuals are likely to have
another source of emotional distress in addition to their
syncope episodes.
Clinical Validity
The SFSQ has been shown to differentiate between patients
with one versus those with more than one episode and between
patients with or without comorbid disorders; it does not dif-
ferentiate between age groups and gender. This could indicate
that the questionnaire is not very discriminative or that the
difference between the selected subgroups was not large enough
forany differences to be detected. The second explanation seems
plausible because the SF-36, particularly the MCS, does not
discriminate between the selected groups either. Another view
could be that the lack of difference is actually a strength of the
instrument because influences from age and gender may arise
from other than syncope-related causes.
Responsiveness
The results of the changes in scores related to changes in
health status (Fig. 1) and the differentiation between patients
with and without recurrences during follow-up indicate that
the responsiveness of the SFSQ is appropriate, especially be-
cause recurrences have been shown to be one of the main
influences on the HR-QoL of patients with TLOC.
7,20,21,24
Although the SFSQ was not responsive to changes in HR-QoL
in patients with different diagnoses, earlier studies have shown
that the difference in the HR-QoL of patients with different
diagnoses is modest.
7 It therefore seems that other factors are
more important contributors to QoL. One possible explanation
could be that patients interpret the questions to be related to
the moment of an episode instead of their daily life. To prevent
this issue, a clearer time frame could be added to the ques-
tionnaire, for instance, focusing patients on the last 4 weeks.
Clinical Application of the Instrument
The SFSQ can provide important information on the effect of
interventions on HR-QoL of patients, especially in moderately
or severely affected patients. With minimal amendments to the
instrument, the SFSQ could also be reliable in less affected
groups of patients. We recommend that this instrument be
used primarily in group-comparisons in trials comparing
diagnostic tests or treatment effects. As well, it could be a
viable option in cohort-studies, where patients are compared
over different time points. Furthermore, we feel that individual
Figure 1. Mean changes on scales of the SFSQ related to change
in clinical status of the patient over 1 year (much better, somewhat
better, equal, somewhat worse, much worse) measured by health
transition question of SF-36 for n=268 patients. Drop in score
indicates improvement of patient. Imp impairment score;
F/W fear–worry score.
Table 4. Known-group comparison: discriminative properties of the Syncope Functional Status Questionnaire between mutually exclusive
subgroups differing in sociodemographic and clinical status
Age
<50 vs ≥50
Episodes TLOC year
before presentation
1v s> 1
Charlson index
0v s≥1
Gender
Male–Female
n 179 206 166 222 163 197 271 114
Mean ± SD 35±9.1 66±11
Median (min–max) 1 3 (2–150) 0 1 (1–10)
Impairment score −4.5 (−11.4 to 2.4) −12.5* (−19.5 to −5.5) −11.3* (−19 to −3.5) −5.7 (−13 to 1.3)
(mean difference; 95% CI)
Fear–worry score 1.9 (−3.8 to 7.6) −10.3* (−16 to −4.7) 1.3 (−4.9 to 7.6) −2.9 (−8.7 to 2.8)
(mean difference; 95% CI)
Syncope Dysfunction Score −0.7 (−6.2 to 4.8) −12.2* (−18 to −6.6) −4.7 (−11 to 1.4) −4.8 (−11 to 0.7)
(mean difference; 95% CI)
*Statistically significant difference (p<.05)
1284 van Dijk et al.: Validation of a Syncope HR-QoL Questionnaire JGIMpatient SFSQ scores could be informative for the physician,
giving the physician an impression of the patient’s fear and
worry and general experience as a result of the episodes.
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